Millennium

FDA approves Imbruvica for rare blood cancer

Wednesday, November 13, 2013 04:13 PM

The FDA has approved Imbruvica (ibrutinib) to treat patients with mantle cell lymphoma (MCL), a rare and aggressive type of blood cancer.

More... »

Quest Diagnostics

Former Millennium CEO Deborah Dunsire joins EnVivo as president and CEO

Friday, July 12, 2013 01:57 PM

EnVivo Pharmaceuticals, developing a range of novel therapies for central nervous system (CNS) diseases, has named Deborah Dunsire, M.D., president and chief executive officer. She also joins the company's board of directors. Dunsire brings more than 25 years of scientific, clinical, operational and commercial experience and biological and pharmaceutical industry leadership to EnVivo.

More... »


Third Rock Ventures expands, strengthens team

Wednesday, May 15, 2013 09:38 AM

Third Rock Ventures, a venture capital firm focused on building healthcare companies, has expanded and strengthened its team with several appointments and role changes. These additions allow Third Rock to continue to support the launch of new companies focused on disruptive areas of science and medicine, the maturation and development of its current portfolio companies and the overall strategy and direction of the firm.

More... »

Parexel CEO Rickenbach to receive MassBio’s Henri Termeer Innovative Leadership Award

Monday, March 11, 2013 02:35 PM

Josef von Rickenbach, chairman and CEO of Parexel International, a global bio/pharmaceutical services organization, will be honored for his commitment and contributions to the biotechnology industry, by the Massachusetts Biotechnology Council (MassBio), a not-for-profit organization that represents and provides services and support for the Massachusetts biotechnology industry.

More... »

Genentech and Novartis rank as image leaders among oncologists, hematologists

Wednesday, July 25, 2012 09:59 AM

Genentech and Novartis have the best image among oncologists and hematologists, according to Market Strategies International, a market research consultancy that recently completed its 2012 Oncology Image Study.

More... »

The CenterWatch Monthly, May 2012

Tuesday, May 1, 2012 08:00 AM

Newer sites most optimistic about the future

More... »

Seattle Genetics, Millennium, Ventana collaborate on companion diagnostic test for Adcetris

Friday, April 13, 2012 12:37 PM

Seattle Genetics and Millennium, a subsidiary of Takeda Pharmaceutical, have formed a collaboration with Ventana Medical Systems, a member of the Roche Group, through which Ventana will seek to develop, manufacture and commercialize a molecular companion diagnostic test with the goal of identifying patients who might respond to treatment with Adcetris based on CD30 expression levels in their tissue specimens.

More... »

Presage and Millennium enter cancer research agreement

Monday, April 9, 2012 09:59 AM

Presage Biosciences, a Seattle, Wash.-based company that identifies clinically viable oncology drug combinations, has entered into a cancer research agreement with Millenium, Takeda’s oncology arm based in Cambridge, Mass.

More... »

Interim data released on phase I Adcetris trial

Friday, January 27, 2012 02:01 PM

Seattle Genetics and Millennium, the Takeda oncology company, released interim results from 32 patients treated to date in a phase I clinical trial of Adcetris (brentuximab vedotin) administered in combination or sequentially with chemotherapy for the treatment of newly diagnosed systemic anaplastic large cell lymphoma (sALCL) and other CD30-positive mature T-cell lymphoma patients.

More... »

Takeda to acquire Intellikine for $190 million

Wednesday, December 21, 2011 01:31 PM

Takeda Pharmaceutical and Intellikine have entered into an agreement for Takeda America Holdings to acquire Intellikine by cash. Takeda expects that the transaction will be finalized in January 2012. Under the agreement, Takeda America Holdings will acquire Intellikine for $190 million upfront and up to $120 million in additional potential clinical development milestone payments.

More... »


CWWeekly

May 18

Research for All Act reaches Congress for second time seeking gender equality in basic research, clinical trials

MediciGlobal finds fewer trial dropouts among participants who actively pursue enrollment versus those recruited

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs